Total trials
180
Active
18
Phase 3
59
Total enrollment
94,877
Pipeline matrix
Showing 20 of 20 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide | — | — | — | — | — | 1 | |
| Foster® 200/6 pMDI | — | — | — | — | — | 1 | |
| Metreleptin | — | — | — | — | 3 | ||
| CHF10196 | — | — | — | — | 2 | ||
| PRX-102 1 mg/kg every 2 weeks | — | — | — | — | — | 1 | |
| PRX-102 2 mg/kg every 4 weeks | — | — | — | — | — | 1 | |
| Experimental: Participant Group CHF 5993 pMDI HFA-152a | — | — | — | — | — | 1 | |
| Oleogel-S10 | — | — | — | — | — | 1 | |
| PRX-102 1 mg/kg every two weeks | — | — | — | — | — | 1 | |
| CHF6333 | — | — | — | — | 2 | ||
| CHF5993 pMDI with HFA-152a | — | — | — | — | — | 1 | |
| CHF5993 pMDI with HFA-134a | — | — | — | — | — | 1 | |
| CHF718 pMDI with HFA-134a | — | — | — | — | — | 1 | |
| CHF6333 Placebo | — | — | — | — | — | 1 | |
| CHF10067 | — | — | — | — | — | 1 | |
| CHF6467 Part 1 | — | — | — | — | — | 1 | |
| CHF6467 Part 2 | — | — | — | — | — | 1 | |
| Pantoprazole | — | — | — | — | — | 1 | |
| Velmanase Alfa | — | — | — | 4 | |||
| Pegunigalsidase-alfa | — | — | — | — | — | 1 |
Next readouts
- 2026-03
- 2026-07-21
- 2026-08
- 2026-08-11
- 2026-12-09
- 2027-06-03
- 2027-10
- 2028-02-12
- 2028-03
- 2028-06-13
Top conditions
- Asthma54
- Chronic Obstructive Pulmonary Disease33
- COPD14
- Chronic Obstructive Pulmonary Disease (COPD)9
- Fabry Disease8
- Alpha-Mannosidosis6
- Cystic Fibrosis6
- Bronchial Asthma4
Frequently asked questions about Chiesi Farmaceutici S.p.A.
- How many clinical trials does Chiesi Farmaceutici S.p.A. have on ClinicalTrials.gov?
- Chiesi Farmaceutici S.p.A. is listed as the lead sponsor on 180 clinical trials in ClinicalTrials.gov, 18 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Chiesi Farmaceutici S.p.A.'s trials are in Phase 3?
- 59 of Chiesi Farmaceutici S.p.A.'s trials are in Phase 3, spread across 20 active drug programs.
- What therapeutic areas does Chiesi Farmaceutici S.p.A. focus on?
- Chiesi Farmaceutici S.p.A.'s most-studied conditions on ClinicalTrials.gov are Asthma, Chronic Obstructive Pulmonary Disease, COPD, Chronic Obstructive Pulmonary Disease (COPD), Fabry Disease.
- When are Chiesi Farmaceutici S.p.A.'s next clinical trial readouts?
- Chiesi Farmaceutici S.p.A. has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa”, expected around 2026-03.